Quince Therapeutics, Inc. (QNCX)
NASDAQ: QNCX · Real-Time Price · USD
1.325
-0.025 (-1.85%)
Mar 31, 2025, 10:55 AM EDT - Market open
Quince Therapeutics Employees
Quince Therapeutics had 32 employees as of December 31, 2023. The number of employees increased by 11 or 52.38% compared to the previous year.
Employees
32
Change (1Y)
11
Growth (1Y)
52.38%
Revenue / Employee
n/a
Profits / Employee
-$1,775,875
Market Cap
58.30M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
QNCX News
- 6 days ago - Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results - Business Wire
- 7 weeks ago - Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia - Business Wire
- 7 weeks ago - Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Business Wire
- 7 weeks ago - Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia - Business Wire
- 2 months ago - Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia - Business Wire
- 2 months ago - Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia - Business Wire
- 2 months ago - Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board - Business Wire
- 4 months ago - Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results - Business Wire